Repligen Corporation (RGEN) News
Filter RGEN News Items
RGEN News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest RGEN News From Around the Web
Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda -...
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Repligen's bioprocessing products are helping customers fast-track Coronavirus vaccines and therapies.
Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
* Reports record quarterly revenue of $87.5 million * Overall revenue grew 24% year-over-year, with organic growth of 19% * Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth * Completes acquisition of silicone molding and tubing manufacturer Engineered Molding TechnologyWALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.Tony J. H...
Repligen (NASDAQ:RGEN) is scheduled to announce Q2 earnings results on Thursday, July 30th, before market open.The consensus EPS Estimate is $0.16 (-48.4% Y/Y) and the consensus Revenue Estimate is $78.39M (+10.9% Y/Y).Over the last 2 years, RGEN has beaten EPS estimates 75% of the time and has beaten revenue estimates...
Repligen is building a base and near a possible buy range ahead of its next quarterly earnings report, expected on or around Jul. 30.
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (RGEN) Outperforming Other Medical Stocks This Year?
EXEL vs. RGEN: Which Stock Is the Better Value Option?